Effectiveness of local hormone therapy depending of duration postmenopausal, mineral bone density, level estrogen receptor in patients with sclerosing lichen vulva

• Babaeva Nataliya A.
• Antonova Irina B.
• Aleshikova Olga I.
• Ivashina Svetlana V.
• Igor I. Baranov
• Zukhra K. Uzdenova
• Ashrafyan Lev A.

Abstract

The problem of dystrophic diseases and vulvar cancer still remains unresolved. Most of the researchers to the main etiological causes of these diseases, include disorders in the system of neuroendocrine homeostasis that occur in postmenopausal women. Along with this, a reduction in the level of estrogen receptors in the tissue of the vulva, which forms in postmenopause, is also of some importance. Knowledge of the receptor status of the vulvar tissue in this pathology in postmenopausal patients allows for a differential construction of a hormonal therapy program. For an adequate realization of the hormonal effect, not only the presence of a hormone in peripheral blood is necessary, but also a sufficient level in the tissues - targets of specific receptors. The response of tissues to the effects of steroid hormones is determined by the concentration of receptors, their structure and the properties of hormones. The local effect of steroid hormones is realized by passive diffusion into the cells of the body. The priority role in the choice of therapy for atrophic disorders, caused by a decrease in gonad function, belongs to estriol-containing drugs. This is due to the specific local sensitivity of the tissues of the lower parts of the urogenital tract to estriol. There are several criteria that determine the indications and possible prognosis when performing hormone therapy in patients with sclerotic lichen. These include bone mineral density and estrogen-receptor level in the vulvar tissue, depending on the length of the postmenopausal period.

Keywords:sclerotic lichen of the vulva, hormone therapy, estrogen-receptors

References

1. Smetnik VP, Tumilovich L. G. Non-operative gynecology. Saint Petersburg: SOTIS, 1995. (in Russian)

2. Kostava M.N. Dystrophic diseases of the vulva. Diseases of the cervix, vagina and vulva. Edit. by V.N. Prilepskaya. Моscow: MEDpress, 1999: 326-36. (in Russian)

3. Forcucci-Zulli M., Gaglione R., et al. Sex steroid receptors in normal and malignant human vulvar tissue. Gynecol Obstet Invest. 1985; 19 (2): 103-6.

4. Garau J.M., Paola G.R., Charreau E.N. Estrogen and progesterone receptors assays on the vulvar epitelium. J Reprod Med. 1986; 31 (10): 987-91.

5. Hodgins M.B., Spike R.C., et al. Immunohistochemical investigation of androgen, estrogen and progesterone receptors in vulva and vagina. Br J Obstet Gynecol. 1998; 105 (2): 216-22.

6. MacLean A.B., Nicol L.A., Hodgins M.B. Immunohistochemical localization of estrogen receptors in the vulva and vagina. J Reprod Med. 1990; 35 (11): 1015-6.

7. Omsjo I.H., Wright P.B., Bormer O.P. Estrogen and progesterone receptors in normal and malignant vulvar tissue. Gynecol Obstet Invest. 1984; 17 (6): 281-3.

8. Steroid hormone receptors in human tumors. Edited by A.S. Bas-salyk. Moscow: Meditsina, 1987.

9. Balan V.E. Urogenital disorders in menopause (clinic, diagnosis, hormone replacement therapy). Autoabstract of Diss. Moscow, 1998. (in Russian)

10. Utian W.H. The place of oestriol therapy after menopause. Acta Endocrinol Suppl. (Copenh). 1980; 233: 51-6.

11. Bachman G.A., Notelovitz M. Long-term non hormonal treatment of vaginal dryness. Maturitas. 1995; 22: 1-5.

12. Fruchter R., Melnick L., Pomeranz M.K. Lichenoid vulvar disease: a review. Int J Womens Dermatol. 2017; 3 (1): 58-64.

13. Prilepskaya V.N., Smetnik V.P. The power of the fourth generation. StatusPraesens. Ginekologiya, akusherstvo, besplodnyy brak [StatusPraesens. Gynecology, Obstetrics, Barren Marriage]. 2019. № 2 (4): 29-35.2019; 2 (4): 29-35. (in Russian)

14. Ashrafyan L.A., Antonova I.B., Basova I.O., Babaeva N.A. Cancer of the vulva, endometrium, postmenopausal ovaries. Opukholi zhenskoy reproduktivnoy sistemy [Tumors of Female Reproductive System]. 2007; (4): 72-8. (in Russian)

15. Ashrafyan L.A., Kharchenko N.V., Akopova N.B., Ivashina S.V. Four pathogenetic variants of changes in the genitals in women in menopause.. Klimakteriy [Menopause]. 2001; (3): 7. (in Russian)

16. Ashrafyan L.A., Kharchenko N.V., Babaeva N.A., et al. The state of the receptor apparatus of the vulva with sclerotic lichen.Vestnik RUDN [Bulletin of Russian Peoples' Friendship University]. 2006; (1): 88-94. (in Russian)

17. Clark J.H., Paszko Z. Nuklear binding and retention of the receptor estrogen complex: relation the agonistic and antagonistic properties of estriol. Endocrinology. 1997; 100 (1): 91-6.

18. Press M.F., Nousek-Goebl N.A., Bur M. Estrogen receptors localization in the female genital tract. Am J Pathol. 1986; 123: 28092.

19. Serov V.N., Abubakirova A.M., Baranov I.I. Efferent treatments for pathological conditions in obstetrics Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 1997; (5): 64. (in Russian)

20. Bershtein LM. Hormonal carcinogenesis. St. Petersburg, 2000: 133-8. (in Russian)

21. Smetnik V.P. Systemic changes in women in menopause. Russkiy meditsinskiy zhurnal [Russian Medical Journal]. 2001; 9 (9): 354-7. (in Russian)

22. Becagli L., Scrimin F., De Salva D., et al. Hormone receptors in dystrophic and neoplastic vulvar disease. Preliminary consideration. Clin Exp Obstet Gynecol. 1983; 23: 145-9.

23. Nappi R.E., Murina F., Perrone G., Villa P., et al. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol. 2017; 69 (4): 37080.

24. Cohen P.A., Anderson L., Eva L., Scurry J., et al. Clinical and molecular classification of vulvar squamous pre-cancers. Int J Gynecol Cancer. 2019; 29 (4): 821-8.

25. Ali E.S., Mangold C., Peiris A.N. Estriol: emerging clinical benefits. Menopause. 2017; 24 (9): 1081-5.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)